NCNicholas C. Cullen

Nicholas C. Cullen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicholas C. Cullen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reducing unnecessary tau-PET scans in a memory clinic setting via blood-based biomarker screening

    by Nicholas Cullen, Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist, Wagner Braum, Henrik Zetterberg, Giovanni Frisoni, Nicholas Ashton, Kaj Blennow, Niklas Mattsson-Carlgren, et al.

    Tau-PET provides valuable prognostic information in Alzheimer’s disease but using blood-based biomarkers as a first-line screening tool could reduce costs. In this study, plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in 550 memory clinic patients who had subjective cognitive decline, mild cognitive impairment, or any form of dementia from the Swedish BioFINDER-2 study. For each biomarker, cutoffs were established to achieve 90% sensitivity for detecting tau-PET positivity. The percentage of participants who fell below the cutoff was calculated along with the tau-PET positive rate among participants with abnormal biomarker values. Results showed that between 18–51% of tau-PET scans could be saved with plasma screening, with P-tau217 performing best. Performance of GFAP, P-tau181, and P-tau231 was in a second tier. The PET positive rate among those who would receive a tau-PET scan was ~ 75% with plasma screening compared to 37% in the entire study population.

  • Open Access

    Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models

    by Nicholas C. Cullen, Shorena Janelidze, Niklas Mattsson‐Carlgren, Sebastian Palmqvist, Tobias Bittner, Ivonne Suridjan, Alexander Jethwa, Gwendlyn Kollmorgen, Wagner S. Brum, Henrik Zetterberg, et al.

    Introduction: The effect of random error on the performance of blood‐based biomarkers for Alzheimer's disease (AD) must be determined before clinical implementation.Methods: We measured test‐retest variability of plasma amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau (p‐tau)217 and simulated effects of this variability on biomarker performance when predicting either cerebrospinal fluid (CSF) Aβ status or conversion to AD dementia in 399 non‐demented participants with cognitive symptoms.Results: Clinical performance was highest when combining all biomarkers. Among single‐biomarkers, p‐tau217 performed best. Test‐retest variability ranged from 4.1% (Aβ42/Aβ40) to 25% (GFAP). This variability reduced the performance of the biomarkers (≈ΔAUC [area under the curve] −1% to −4%) with the least effects on models with p‐tau217. The percent of individuals with unstable predicted outcomes was lowest for the multi‐biomarker combination (14%).Discussion: Clinical prediction models combining plasma biomarkers—particularly p‐tau217—exhibit high performance and are less effected by random error. Individuals with unstable predicted outcomes (“gray zone”) should be recommended for further tests.


  • Open Access

    Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline

    by Nicholas Cullen, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson, For The Alzheimer’s Disease Neuroimaging Initiative

    Background and Objective Experimental studies suggest that the balance between short and long β-amyloid (Aβ) species might modulate the toxic effects of Aβ in Alzheimer disease (AD), but clinical evidence is lacking. We studied whether Aβ38 levels in CSF relate to risk of AD dementia and cognitive decline. Methods CSF Aβ38 levels were measured in 656 individuals across 2 clinical cohorts: the Swedish BioFINDER study and the Alzheimer9s Disease Neuroimaging Initiative (ADNI). Cox regression models were used to evaluate the association between baseline Aβ38 levels and risk of AD dementia in AD biomarker–positive individuals (AD+; determined by CSF phosphorylated tau [P-tau]/Aβ42 ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Linear mixed-effects models were used to evaluate the association between baseline Aβ38 levels and cognitive decline as measured by the Mini-Mental State Examination (MMSE) in AD+ participants with SCD, MCI, or AD dementia. Results In the BioFINDER cohort, high Aβ38 levels were associated with slower decline in MMSE score (β = 0.30 points per SD, p = 0.001) and with lower risk of conversion to AD dementia (hazard ratio 0.83 per SD, p = 0.03). In the ADNI cohort, higher Aβ38 levels were associated with less decline in MMSE score (β = 0.27, p = 0.01) but not risk of conversion to AD dementia (p = 0.66). Aβ38 levels in both cohorts were significantly associated with both cognitive and clinical outcomes when further adjusted for CSF P-tau or CSF Aβ42 levels. Discussion Higher CSF Aβ38 levels are associated with lower risk of AD-related changes in 2 independent clinical cohorts. These findings suggest that γ-secretase modulators could be effective as disease-altering therapy. Trial Registration Information ClinicalTrials.gov Identifier: NCT03174938.


  • Open Access

    CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators

    by Nicholas C. Cullen, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson

    Objective Shorter Aβ species might modulate disease progression in Alzheimer’s disease (AD). Here we studied whether Aβ38 levels in cerebrospinal fluid (CSF) are associated with risk of developing AD dementia and cognitive decline. Methods CSF Aβ38 levels were measured in 656 individuals across two clinical cohorts – the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cox regression models were used to evaluate the association between baseline Aβ38 levels and risk of AD dementia in AD-biomarker positive individuals (AD+; determined by CSF P-tau/Aβ42 ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Linear mixed effects models were used to evaluate the association between baseline Aβ38 levels and cognitive decline as measured by MMSE in AD+ participants with SCD, MCI or AD dementia. Results In the BioFINDER cohort, high Aβ38 levels were associated with slower decline in MMSE (β = 0.30 points / sd., P = 0.001) and with lower risk of conversion. To AD dementia (HR = 0.83 per sd., P = 0.03). In the ADNI cohort, higher Aβ38 levels were associated with less decline in MMSE (β = 0.27, P = 0.01), but not risk of conversion to AD dementia (P = 0.66). Aβ38 levels in both cohorts remained significantly associated with both outcomes when adjusted for CSF P-tau levels and remained associated with cognition when adjusted for CSF Aβ42 levels. Conclusions Higher CSF Aβ38 levels are associated with lower risk of AD-related changes in two independent clinical cohorts. These findings may have implications for γ-secretase modulators as potential disease-altering therapy.


  • Open Access

    Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition

    by Nicholas C. Cullen, A Nders Mälarstig, Erik Stomrud, Oskar Hansson, Niklas Mattsson-Carlgren

    It is unclear how pathological aging of the inflammatory system relates to Alzheimer’s disease (AD). We tested whether age-related inflammatory changes in cerebrospinal fluid (CSF) and plasma exist across different stages of AD, and whether such changes related to AD pathology. Linear regression was first used model chronological age in amyloid-β negative, cognitively unimpaired individuals (Aβ− CU; n = 312) based on a collection of 73 inflammatory proteins measured in both CSF and plasma. Fitted models were then applied on protein levels from Aβ+ individuals with mild cognitive impairment (Aβ+ MCI; n = 150) or Alzheimer’s disease dementia (Aβ+ AD; n = 139) to test whether the age predicted from proteins alone (“inflammatory age”) differed significantly from true chronological age. Aβ− individuals with subjective cognitive decline (Aβ− SCD; n = 125) or MCI (Aβ− MCI; n = 104) were used as an independent contrast group. The difference between inflammatory age and chronological age (InflammAGEscore) was then assessed in relation to core AD biomarkers of amyloid, tau, and cognition. Both CSF and plasma inflammatory proteins were significantly associated with age in Aβ− CU individuals, with CSF-based proteins predicting chronological age better than plasma-based counterparts. Meanwhile, the Aβ− SCD and validation Aβ− CU groups were not characterized by significant inflammatory aging, while there was increased inflammatory aging in Aβ− MCI patients for CSF but not plasma inflammatory markers. Both CSF and plasma inflammatory changes were seen in the Aβ+ MCI and Aβ+ AD groups, with varying degrees of change compared to Aβ− CU and Aβ− SCD groups. Finally, CSF inflammatory changes were highly correlated with amyloid, tau, general neurodegeneration, and cognition, while plasma changes were mostly associated with amyloid and cognition. Inflammatory pathways change during aging and are specifically altered in AD, tracking closely with pathological hallmarks. These results have implications for tracking AD progression and for suggesting possible pathways for drug targeting.


  • Open Access

    Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease

    by Oskar Hansson, Nicholas Cullen, Henrik Zetterberg, The Alzheimer’s Disease Neuroimaging Initiative, Kaj Blennow, Niklas Mattsson‐Carlgren

    We examined if plasma phosphorylated tau is associated with neurodegeneration in Alzheimer’s disease. We investigated 372 cognitively unimpaired participants, 554 mild cognitive impairment patients, and 141 Alzheimer’s disease dementia patients. Tau phosphorylated at threonine 181, regional cortical thickness (using magnetic resonance imaging) and hypometabolism (using fluorodeoxyglucose positron emission tomography) were measured longitudinally. High plasma tau was associated with hypometabolism and cortical atrophy at baseline and over time, and longitudinally increased tau was associated with accelerated atrophy, but these associations were only observed in Aβ‐positive participants. Plasma phosphorylated tau may identify and track processes linked to neurodegeneration in Alzheimer’s disease.


  • Open Access

    Comparing progression biomarkers in clinical trials of early Alzheimer’s disease

    by Nicholas C. Cullen, Henrik Zetterberg, Philip S. Insel, Bob Olsson, Ulf Andreasson, The Alzheimer’s Disease Neuroimaging Initiative, Kaj Blennow, Oskar Hansson, Niklas Mattsson‐Carlgren

    Objective: To investigate the statistical power of plasma, imaging, and cognition biomarkers as Alzheimer’s disease (AD) clinical trial outcome measures.Methods: Plasma neurofilament light, structural magnetic resonance imaging, and cognition were measured longitudinally in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in control (amyloid PET or CSF Aβ42 negative [Aβ‐] with Clinical Dementia Rating scale [CDR] = 0; n = 330), preclinical AD (Aβ + with CDR = 0; n = 218) and mild AD (Aβ + with CDR = 0.5‐1; n = 697) individuals. A statistical power analysis was performed across biomarkers and groups based on longitudinal mixed effects modeling and using several different clinical trial designs.Results: For a 30‐month trial of preclinical AD, both the temporal composite and hippocampal volumes were superior to plasma neurofilament light and cognition. For an 18‐month trial of mild AD, hippocampal volume was superior to all other biomarkers. Plasma neurofilament light became more effective with increased trial duration or sampling frequency. Imaging biomarkers were characterized by high slope and low within‐subject variability, while plasma neurofilament light and cognition were characterized by higher within‐subject variability.Interpretation: MRI measures had properties that made them preferable to cognition and pNFL as outcome measures in clinical trials of early AD, regardless of cognitive status. However, pNfL and cognition can still be effective depending on inclusion criteria, sampling frequency, and response to therapy. Future trials will help to understand how sensitive pNfL and MRI are to detect downstream effects on neurodegeneration of drugs targeting amyloid and tau pathology in AD.


  • Open Access

    Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment

    by Nicholas C. Cullen, Antoine Leuzy, Sebastian Palmqvist, Shorena Janelidze, Erik Stomrud, Pedro Pesini, Leticia Sarasa, José Antonio Allué, Nicholas K. Proctor, Henrik Zetterberg, et al.

    We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI), using plasma biomarkers of β-amyloid (Aβ), tau, and neurodegeneration. We included MCI patients from the Swedish BioFINDER study (n=148) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI; n=86 for model selection; n=425 for prognostic validation). The primary outcomes were longitudinal cognition and conversion to AD dementia, predicted by plasma Aβ42/Aβ40, P-tau181, and neurofilament light (NfL). A model which included P-tau181 and NfL, but not Aβ42/Aβ40, had the best performance (AUC=0.88 for four-year conversion to AD in BioFINDER, validated in ADNI). The prognostic ability of plasma biomarkers was stronger than a basic model of age, sex, education, and baseline cognition and similar to cerebrospinal fluid biomarkers. Plasma biomarkers, in particular P-tau181 and NfL, may be of high value to identify MCI individuals who will progress to AD dementia in clinical trials and in clinical practice.